A NEW UPLOAD OF" Anti hypertensive therapeutics in asia-pacific markets to 2021 - increasing prevalence of hypertension drives market growth despite weak pipeline"

1. Get Full report with Table of Contents:
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
YRH: Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 -
Increasing Prevalence of Hypertension Drives Market Growth despite Weak
Pipeline
Overview, Size, Share, Analysis, Technology Developments, Development
Status, Trends, Structure, Production Value and Forecast Research Report
Get Full Report with Table of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing
Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
Summary:
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
Summary
Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries.
It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual
Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China,
India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a
major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients,
and the public alike, leading to poor blood pressure control.
The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors
(ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin
inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination
therapy (including fixed-dose combinations) varies from country to country. The most commonly
prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are
telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and
eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril,
and quinapril dominate the ACEIs.
Scope
- Hypertension prevalence is a prominent contributor to market size in the assessed countries. The
market is mostly dominated by generics, and there are only a few patented products.

2. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various
stages of development, dominated by small molecules.
- Will the upcoming molecules change the treatment paradigm in the near future?
- How will the weak pipeline affect the market?
- Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of
attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of
action?
- How do other factors such as average trial duration and trial size influence the costs and risks
associated with product development?
- Over the 2014–2021 forecast period, the APAC anti-hypertensive therapeutics market is expected
to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9 billion. Growth is
projected to vary considerably across the four assessed markets.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will branded products’ patent expirations pose a significant threat?
- Will new market entrants over the forecast period lead to substantial changes in annual therapy
costs?
Reasons to buy
This report will enable you to -
- Understand the clinical context of hypertension by considering symptoms, etiology,
pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed
products landscape, and recognize gaps.
- Appreciate key anti-hypertensive pipeline trends in molecule type, administration route,
mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical
trial size, duration, and failure rate by stage of development, molecule type, and mechanism of
action.

3. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
- Compare treatment usage patterns, annual therapy costs, and market growth projections for the
China, India, Australia, and Japan.
- Discover trends in licensing and co-development deals concerning anti-hypertensive products and
identify the major strategic consolidations that have shaped the commercial landscape.
Get Full Report with Table of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Pathophysiology 9
2.2 Etiology 10
2.3 Signs and Symptoms 11
2.4 Co-morbidities and Complications 11
2.5 Diagnosis 13
2.5.1 Office or Clinic Blood Pressure Monitoring 13
2.5.2 Ambulatory Blood Pressure Monitoring 14
2.5.3 Home Blood Pressure Monitoring 14
2.5.4 Miscellaneous Methods 14
2.5.5 Diagnosis of Target Organ Damage 14
2.5.6 Diagnosis of Hypertension in Pregnancy 15
2.6 Classification 15
2.7 Epidemiology 16
2.8 Prognosis 17
2.9 Treatment and Management 17
2.9.1 Treatment Strategy 19
3 Marketed Products 26
3.1 Key Marketed Products 26
3.1.1 Prestalia (perindopril arginine + amlodipine besylate) 26
3.1.2 Azilva (azilsartan medoxomil) 26
3.1.3 Amlodipine besylate 26
3.1.4 Telmisartan 27
3.1.5 Aliskiren 28
3.1.6 Olmesartan medoxomil 29
3.1.7 Valsartan 30
3.1.8 Losartan 31
3.1.9 Exforge (amlodipine + valsartan) 32
3.2 Heat Map for Marketed Products 33
4 Anti-hypertensive Market to 2021 – Pipeline Products 35
4.1 Overall Pipeline 35

4. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
4.1.1 Pipeline Analysis by Molecule Type 36
4.1.2 Pipeline Analysis by Mechanism of Action 37
4.2 Clinical Trial Analysis 39
4.2.1 Failure Rate 39
4.2.2 Clinical Trial Size 41
4.2.3 Duration 42
4.3 Promising Drug Candidates in Pipeline 43
4.3.1 SER-100 43
4.3.2 CS-3150 43
5 Market Forecast to 2021 44
5.1 Asia-Pacific Market 44
5.1.1 Treatment Use Patterns 45
5.1.2 Market Size 46
5.2 Australia 47
5.2.1 Treatment Use Patterns 47
5.2.2 Annual Cost of Therapy 47
5.2.3 Market Size 48
5.3 India 49
5.3.1 Treatment Use Patterns 49
5.3.2 Annual Cost of Therapy 49
5.3.3 Market Size 50
5.4 China 51
5.4.1 Treatment Use Patterns 51
5.4.2 Annual Cost of Therapy 51
5.4.3 Market Size 52
5.5 Japan 53
5.5.1 Treatment Use Patterns 53
5.5.2 Annual Cost of Therapy 53
5.5.3 Market Size 54
5.6 Drivers and Barriers 55
5.6.1 Drivers 55
5.6.2 Barriers 56
6 Deals and Strategic Consolidations 57
6.1 Licensing Agreements 57
6.1.1 Major Licensing Deals 59
6.2 Co-development Agreements 60
6.2.1 Major Co-development Agreements 62
7 Appendix 63
7.1 All Pipeline Drugs by Phase 63
7.1.1 Discovery 63
7.1.2 Preclinical 64
7.1.3 Phase I 66
7.1.4 Phase II 68
7.1.5 Phase III 69
7.2 Market Forecasts to 2021 70
7.2.1 Asia-Pacific 70

5. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
7.2.2 China 70
7.2.3 India 70
7.2.4 Japan 71
7.2.5 Australia 71
7.3 Market Definitions 71
7.4 Abbreviations 72
7.5 References 74
7.6 Research Methodology 78
7.6.1 Coverage 78
7.6.2 Secondary Research 78
7.6.3 Primary Research 79
7.6.4 Therapeutic Landscape 79
7.6.5 Geographical Landscape 81
7.6.6 Pipeline Analysis 82
7.7 Expert Panel Validation 82
7.8 Contact Us 82
7.9 Disclaimer 82
Get Full Report with Table of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
Table of Figures:
1.1 List of Tables
Table 1: Anti-hypertensive Therapeutics, Possible Co-morbidities 12
Table 2: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for
Ambulatory Blood Pressure Measurement (mmHg) 14
Table 3: Anti-hypertensive Therapeutics, Blood Pressure Classification in Adults (mmHg) 15
Table 4: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office
Blood Pressure Levels (mmHg) 16
Table 5: Anti-hypertensive Therapeutics, Prevalence of Hypertension 17
Table 6: Anti-hypertensive Therapeutics, Suggested Medications for Hypertensive Patients with
Certain Medical Conditions 18
Table 7: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations 19
Table 8: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-
hypertensive Drugs 24

6. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
Table 9: Anti-hypertensive Therapeutics, Preference of Drug in Specific Condition/Situation of
Hypertensive Patients 25
Table 10: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Discovery, 2015 63
Table 11: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Preclinical, 2015 64
Table 12: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase I, 2015 66
Table 13: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase II, 2015 68
Table 14: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase III, 2015 69
Table 15: Anti-hypertensive Therapeutics, Asia-Pacific, Market Forecast, 2014–2021 70
Table 16: Anti-hypertensive Therapeutics , China, Market Forecast, 2014–2021 70
Table 17: Anti-hypertensive Therapeutics , India, Market Forecast, 2014–2021 70
Table 18: Anti-hypertensive Therapeutics , Japan, Market Forecast, 2014–2021 71
Table 19: Anti-hypertensive Therapeutics , Australia, Market Forecast, 2014–2021 71
Table 20: Abbreviations 72
Get Full Report with Table of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
About Us:
yourresearchhub Not sure if a research on a topic has ever been conducted? Will an existing
research report go in enough detail? Is the report right for me? Have doubts ?
We’re here to help you.
We at Research Hub, are in the field of connected marketing built by a team of highly
qualified professionals with collective knowledge and expertise in both technology as well as
global marketing.
We bring industry research reports from carefully chosen analysts and publishers across the
globe under a single offering to help our clients with quality research and analysis leading to
actionable insight.
A significant portion of our business is organically sourced and this is where we stand out of
the crowd. Our customers come across us mostly while looking for market insights at
avenues where they are looking for genuine advice. We connect with our clients and

7. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of
Hypertension Drives Market Growth despite Weak Pipeline
actively participate in shaping their research needs – which as a result guaranties a
product that they are sure will benefit them.
Our partners connect with us for the same reasons that our clients conduct their business
with us – the unique model of offering our marketing services. We work very closely with
our partners and bring their strengths to the market in a very effective manner.
Our teams are collocated in India and the UK to provide an unmatched quality of service.
Feel free to contact us at queries@YourResearchHub.Com should you have any questions or
suggestions.
For More Information –
Please call us or write to us:
UK: +44 208123 7101
Email: sales@yourresearchhub.com
Follow Us –
Browse Blog at http://www.yourresearchhub.com/blogs/news